References of "Daly, Adrian"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailClinical characterization of familial isolated pituitary adenomas.
Daly, Adrian ULg; Jaffrain-Rea, M.-L.; Ciccarelli, A. et al

in Journal of Clinical Endocrinology and Metabolism (2006), 91(9), 3316-23

CONTEXT: Familial pituitary adenomas occur rarely in the absence of multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). OBJECTIVE: Our objective was to characterize the clinical and ... [more ▼]

CONTEXT: Familial pituitary adenomas occur rarely in the absence of multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). OBJECTIVE: Our objective was to characterize the clinical and genealogical features of non-MEN1/CNC familial isolated pituitary adenomas (FIPA). DESIGN AND SETTING: We conducted a retrospective study of clinical and genealogical characteristics of FIPA cases and performed a comparison with a sporadic population at 22 university hospitals in Belgium, Italy, France, and The Netherlands. RESULTS: Sixty-four FIPA families including 138 affected individuals were identified [55 prolactinomas, 47 somatotropinomas, 28 nonsecreting adenomas (NS), and eight ACTH-secreting tumors]. Cases were MEN1/PRKAR1A-mutation negative. First-degree relationships predominated (75.6%) among affected individuals. A single tumor phenotype occurred in 30 families (homogeneous), and heterogeneous phenotypes occurred in 34 families. FIPA cases were younger at diagnosis than sporadic cases (P = 0.015); tumors were diagnosed earlier in the first vs. the second generation of multigenerational families. Macroadenomas were more frequent in heterogeneous vs. homogeneous FIPA families (P = 0.036). Prolactinomas from heterogeneous families were larger and had more frequent suprasellar extension (P = 0.004) than sporadic cases. Somatotropinomas occurred as isolated familial somatotropinoma cases and within heterogeneous FIPA families; isolated familial somatotropinoma cases represented 18% of FIPA cases and were younger at diagnosis than patients with sporadic somatotropinomas. Familial NS cases were younger at diagnosis (P = 0.03) and had more frequently invasive tumors (P = 0.024) than sporadic cases. CONCLUSIONS: Homogeneous and heterogeneous expression of prolactinomas, somatotropinomas, NS, and Cushing's disease can occur within families in the absence of MEN1/CNC. FIPA and sporadic cases have differing clinical characteristics. FIPA may represent a novel endocrine neoplasia classification that requires further genetic characterization. [less ▲]

Detailed reference viewed: 27 (6 ULg)
Full Text
Peer Reviewed
See detailLes grandes tailles: quelques grands syndromes et revue de la litterature
Gusbin, Natacha ULg; Verloes, Alain ULg; Daly, Adrian ULg et al

in Revue Médicale de Liège (2006), 61(7-8, Jul-Aug), 572-80

We describe the findings of XYY syndrome in the setting of encountering an individual with this particular condition in the endocrinology clinic. XYY syndrome is a relatively frequent if unfamiliar ... [more ▼]

We describe the findings of XYY syndrome in the setting of encountering an individual with this particular condition in the endocrinology clinic. XYY syndrome is a relatively frequent if unfamiliar condition, which is characterized by taller than average height. The extra Y chromosome may play a role in determining the height of these individuals. From this case, a differential diagnosis of tall stature is outlined, in addition to a description of the principal syndromes associated with gigantism. These primarily include Klinefelter syndrome, Marfan syndrome, androgen resistance and growth hormone excess. These various entities are described from the point of view of their symptomatology, biology, pathophysiology and therapeutic characteristics. [less ▲]

Detailed reference viewed: 102 (6 ULg)
Full Text
See detailIdentification of a family harboring a novel LHBéta subunit mutation associated with hypogonadism
Daly, Adrian ULg; Salvi, R.; Ménagé, J.-J. et al

in The Endocrine Society's - 88th Annual Meeting - Abstract book (2006, June)

Detailed reference viewed: 16 (0 ULg)
See detailDiagnostic Characteristics and Therapeutic Responses in Acromegaly : The Liège Acromegaly Survey
Tikhomirova, M.; Petrossians, Patrick ULg; Daly, Adrian ULg et al

in 50th Meeting of the German Endocrine Society and 23rd Meeting of Dutch Endocrine Society : Essen, Germany, 1-4 March 2006 (2006, March)

Detailed reference viewed: 17 (1 ULg)
See detailSomatostatin analogs in the gastroentestinal tract
Harris, A.; Daly, Adrian ULg; Tichomirowa, M. A. et al

in The handbook of Biologically Active Peptides (2006)

Peptides play a crucial role in many physiological processes including actions as neurotransmitters, hormones, and antibiotics. Research has shown their importance in such fields as neuroscience ... [more ▼]

Peptides play a crucial role in many physiological processes including actions as neurotransmitters, hormones, and antibiotics. Research has shown their importance in such fields as neuroscience, immunology, pharmacology, and cell biology. The Handbook of Biologically Active Peptides presents, for the first time, this tremendous body of knowledge in the field of biologically active peptides in one single reference. The section editors and contributors represent some of the most sophisticated and distinguished scientists working in basic sciences and clinical medicine. The Handbook of Biologically Active Peptides is a definitive, all-encompassing reference that will be indispensable for individuals ranging from peptide researchers, to biochemists, cell and molecular biologists, neuroscientists, pharmacologists, and to endocrinologists. Chapters are designed to be a source for workers in the field and will enable researchers working in a specific area to examine other related areas with which they would not ordinarily be familiar. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailCommentary on : Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg

in Nature Clinical Practice Endocrinology and Metabolism (2006), 2(1), 12-13

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailSerum levels of soluble CD163 correlate with the inflammatory process in coeliac disease.
Daly, Adrian ULg; Walsh, C.; Feighery, C. et al

in Alimentary Pharmacology & Therapeutics (2006), 24(3), 553-9

BACKGROUND: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating ... [more ▼]

BACKGROUND: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. AIM: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. METHODS: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. RESULTS: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). CONCLUSIONS: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease. [less ▲]

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailDesloratadine for allergic rhinitis.
Wilken, Jeffrey A.; Daly, Adrian ULg; Sullivan, Cynthia L. et al

in Expert Review of Clinical Immunology (2006), 2(2), 209-24

Seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) affect up to 40% of the population (depending on geographical area), and are associated with significant morbidity, socioeconomic ... [more ▼]

Seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) affect up to 40% of the population (depending on geographical area), and are associated with significant morbidity, socioeconomic costs and reductions in quality of life. Antihistamines are a first-line therapy, with newer nonsedating agents having superseded sedating first-generation drugs. Desloratadine is a nonsedating, nonimpairing antihistamine that is effective in relieving nasal and non-nasal symptoms of SAR and PAR, including nasal congestion. Desloratadine has a 24-h duration of action, enabling once-daily dosing and providing relief of morning symptoms. Clinical trials have demonstrated that it has no performance impairment, cardiovascular effects or clinically relevant interactions with other tested medications. This article reviews the use of desloratadine in the treatment of SAR and PAR. [less ▲]

Detailed reference viewed: 7 (0 ULg)
See detailPituitary Diseases in Daily Clinical Pratice : Prevalence and Relevance 2006
Jaffrain-Réa, M. L.; Valle, L.; Daly, Adrian ULg et al

in Congrès Italien d'Endocrinologie : Florence, 2006 (2006)

Detailed reference viewed: 4 (0 ULg)
See detailEndocrine abnormalities in McCune-Albright syndrome
Tamagno, G.; Petrossians, Patrick ULg; Daly, Adrian ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 5 (0 ULg)
See detailLes patients acromégales sont-il mal pris en charge? De la mauvaise utilisation des bases de données
Petrossians, Patrick ULg; Tichomirova, M.; Daly, Adrian ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 23 (1 ULg)
See detailThe Liège Acromegaly Survey
Tichomirova, M.; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 10 (2 ULg)
See detailIdentification d'une famille porteuse d'une nouvelle mutation bêta-LH accompagnée d'hypogonadisme
Daly, Adrian ULg; Salvi, R.; Ménagé, J.-J. et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 6 (0 ULg)
Full Text
See detailPathologie inflammatoire de l'hypophyse et grossesse
Hansen, Isabelle ULg; Vroonen, Laurent ULg; Tichomirova, M. et al

in Pathologie hypophysaire et grossesse (2006)

Les affections hypophysaires, tumorales ou non tumorales, sont classiquement responsables d'infertilité. Grâce aux progrès des traitements médicaux et chirurgicaux développés pour le traitement de ces ... [more ▼]

Les affections hypophysaires, tumorales ou non tumorales, sont classiquement responsables d'infertilité. Grâce aux progrès des traitements médicaux et chirurgicaux développés pour le traitement de ces affections hypophysaires, les grossesses sont de plus en plus fréquentes chez les patientes ayant en particulier un adénome hypophysaire sécrétant ou une insuffisance anté-hypophysaire ou un diabète insipide central. Cependant, les conséquences de l'affection hypophysaire et des traitements pour la mère ou le f¿tus sont toujours discutés par les endocrinologues, les gynécologues, les obstétriciens et les pédiatres. Le but de cet ouvrage unique en français est une mise au point de nos connaissances sur le sujet, et tout particulièrement sur le diagnostic hormonal et radiologique d'un syndrome d'hypersécrétion ou d'une insuffisance hypophysaire au cours d'une grossesse, ainsi que sur la prise en charge des patientes présentant une pathologie hypophysaire tumorale ou non tumorale, désirant ou présentant une grossesse. [less ▲]

Detailed reference viewed: 87 (2 ULg)
Full Text
Peer Reviewed
See detailComment j'explore... Une valeur élevée de calcitonine?
Rikir, Estelle ULg; Valdes Socin, Hernan Gonzalo ULg; Vroonen, Laurent ULg et al

in Revue Médicale de Liège (2006), 61(3), 195-200

This article describes a case of lung cancer with associated hypercalcitoninemia in a man with a goitre. The case raises the problem of the differential diagnosis between medullary thyroid carcinoma and a ... [more ▼]

This article describes a case of lung cancer with associated hypercalcitoninemia in a man with a goitre. The case raises the problem of the differential diagnosis between medullary thyroid carcinoma and a neuroendocrine neoplasm with ectopic calcitonin secretion. The article first reviews the physiology of calcitonin, then outlines the diagnostic tests that are required to investigate hypercalcitoninemia and finally discusses the interpretation of test results. [less ▲]

Detailed reference viewed: 134 (8 ULg)
See detailA multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings
Tikhomirova, M.; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 15th Meeting of the Belgian Endocrine Society : Bruxelles, 26 novembre 2005 (2005, November)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailTreatment of pituitary tumors: somatostatin.
Tichomirowa, M. A.; Daly, Adrian ULg; Beckers, Albert ULg

in Endocrine (2005), 28(1), 93-99

Somatostatin is an important physiological regulator of neuroendocrine function across multiple biological systems, including the brain and the gastrointestinal tract. In the pituitary gland, somatostatin ... [more ▼]

Somatostatin is an important physiological regulator of neuroendocrine function across multiple biological systems, including the brain and the gastrointestinal tract. In the pituitary gland, somatostatin regulates the secretion of hormones such as growth hormone and thyroid-stimulating hormone in healthy and pathological states. The short half-life of somatostatin makes it unsuitable for clinical use in chronic diseases, which led to the development of long-acting somatostatin analogs for the treatment of acromegaly and thyroid-stimulating hormone-secreting adenomas, which were administered by intermittent injection twice or three times a day. More recently, depot versions have been developed that permit dosing once every month. This review assesses the efficacy of somatostatin analogs in the treatment of pituitary adenomas, including acromegaly, thyroid-stimulating hormone-secreting tumors, non-functioning adenomas, and Cushing's disease. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailPredictors and rates of treatment-resistant tumor growth in acromegaly
Besser, G. M.; Burman, P.; Daly, Adrian ULg

in European Journal of Endocrinology (2005), 153(2), 187-193

Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of ... [more ▼]

Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of treatment-resistant pituitary tumor growth remains relatively under-explored. Methods: We assessed the literature for relevant data regarding the surgical, medical and radio-therapeutic treatment of acromegaly in order to identify the factors that were predictive of aggressive or treatment-resistant pituitary tumor behavior in acromegaly and undertook an assessment of the rates of failure to control tumor progression with available treatment modalities. Results: Young age at diagnosis, large tumor size, high growth hormone secretion and certain histological markers are predictors of future aggressive tumor behavior in acromegaly. Significant tumor regrowth occurs in less than 10% of cases thought to be cured surgically, whereas failure to control tumor growth is seen in less than 1% of patients receiving radiotherapy. Somatostatin analogs induce a variable degree of tumor shrinkage in acromegaly but up to 2.2% of somatostatin analog-treated tumors continue to grow. Relative to other therapies, limited data are available for pegvisomant, but these indicate that persistent tumor growth occurs in 1.6-2.9% of cases followed up regularly with serial magnetic resonance imaging scans. Conclusions: Treatment-resistant tumor progression occurs in a small minority of patients with acromegaly, regardless of treatment modality. Young patients with large tumors or those with high pre-treatment levels of growth hormone particularly warrant close monitoring for continued tumor progression during treatment for acromegaly. [less ▲]

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailAcromegaly - Pathology, diagnosis and treatment
van der Lely, A. J.; Beckers, Albert ULg; Daly, Adrian ULg et al

Book published by Taylor and Francis Group (2005)

This book reviews the pathophysiology and physical manifestations of acromegaly and discusses the multiple treatment options now available for the management of the patient with acromegaly. The book ... [more ▼]

This book reviews the pathophysiology and physical manifestations of acromegaly and discusses the multiple treatment options now available for the management of the patient with acromegaly. The book contains an ample number of illustrations that help to emphasize points of particular interest, including radiological, histopathological, and physical diagnosis images. Sections are devoted to detailing important topics including determinants of pathological effects of disease activity in acromegaly, individual therapeutic choices and criteria for diagnosis, and disease control. [less ▲]

Detailed reference viewed: 84 (2 ULg)
See detailMale Hypogonadism caused by isolated luteinizing hormone deficiency
Daly, Adrian ULg; Salvi, R.; Petrossians, Patrick ULg et al

in 37th International symposium - GH and Growth Factors in Endocrinology and Metabolism (Athènes Symposium) (2005)

Detailed reference viewed: 12 (1 ULg)